| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043963067 |
| P356 | DOI | 10.2165/00003088-200847110-00002 |
| P698 | PubMed publication ID | 18840026 |
| P5875 | ResearchGate publication ID | 23304474 |
| P2093 | author name string | Neal M Davies | |
| Connie M Remsberg | |||
| Karina R Vega-Villa | |||
| Jody K Takemoto | |||
| Jonathan K Reynolds | |||
| P2860 | cites work | A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. | Q24794291 |
| Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. | Q25257426 | ||
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
| Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials | Q28193800 | ||
| COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter | Q28211053 | ||
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q28218927 | ||
| Global gastrointestinal safety profile of etoricoxib and lumiracoxib | Q28219335 | ||
| Anti-inflammatory and analgesic actions of etoricoxib (an NSAID) combined with misoprostol | Q28573702 | ||
| Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention | Q29620087 | ||
| Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. | Q31842803 | ||
| High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluo | Q32114738 | ||
| A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma | Q33207757 | ||
| Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection | Q33218819 | ||
| Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis | Q33875514 | ||
| Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor | Q33882627 | ||
| Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach | Q33937522 | ||
| Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. | Q33966421 | ||
| Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery | Q33985078 | ||
| The coxibs, selective inhibitors of cyclooxygenase-2. | Q34086325 | ||
| Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. | Q34183755 | ||
| Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor | Q34515171 | ||
| Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers | Q34530443 | ||
| Pharmacokinetics of etoricoxib in patients with renal impairment | Q34544012 | ||
| The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis | Q34558759 | ||
| Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials | Q34565640 | ||
| Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies | Q34570399 | ||
| Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. | Q34575707 | ||
| Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q34582722 | ||
| Celecoxib inhibits 5-lipoxygenase | Q34656902 | ||
| Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat | Q35545077 | ||
| Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials | Q35680546 | ||
| Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?--Not as easy as 1, 2, 3. | Q35887563 | ||
| Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis | Q35954438 | ||
| Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors | Q36108232 | ||
| Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor | Q36120809 | ||
| An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices | Q36189859 | ||
| Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal | Q36673018 | ||
| Efficacy of the newest COX-2 selective inhibitors in rheumatic disease | Q36907440 | ||
| The analgesic effect of etoricoxib relative to that of cetaminophen analgesics: a randomized, controlled single-dose study in acute dental impaction pain | Q39367338 | ||
| The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial | Q39376666 | ||
| Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study | Q39379167 | ||
| A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model | Q39381510 | ||
| Relationship between naproxen plasma concentration and its anti-inflammatory effect in experimental hepatitis | Q40685829 | ||
| Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications | Q41195345 | ||
| Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique | Q41990256 | ||
| Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS. | Q42163336 | ||
| In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). | Q43591309 | ||
| Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers | Q43754371 | ||
| ??? | Q28199855 | ||
| Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial | Q43997545 | ||
| A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. | Q44103550 | ||
| Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. | Q44123837 | ||
| Determination of etoricoxib in human plasma by liquid chromatography–tandem mass spectrometry with electrospray ionisation | Q44410333 | ||
| Characterization of etoricoxib, a novel, selective COX-2 inhibitor | Q44484802 | ||
| Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment | Q44601145 | ||
| A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis | Q44700625 | ||
| Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial | Q44762080 | ||
| The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. | Q45040968 | ||
| Isolation and structural characterization of the photolysis products of etoricoxib. | Q45215294 | ||
| Validated liquid chromatographic ultraviolet method for the quantitation of Etoricoxib in human plasma using liquid-liquid extraction | Q45233715 | ||
| Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs | Q45257806 | ||
| In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions | Q46347800 | ||
| Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib | Q46382423 | ||
| Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial | Q46428706 | ||
| Effects of etoricoxib on the pharmacokinetics of phenytoin. | Q46621565 | ||
| Analysis of interaction between etoricoxib and tramadol against mechanical hyperalgesia of spinal cord injury in rats | Q46719088 | ||
| Validation of a capillary zone electrophoresis method for the comparative determination of etoricoxib in pharmaceutical formulations | Q46858041 | ||
| Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans | Q46905036 | ||
| Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). | Q46927526 | ||
| Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet | Q46958920 | ||
| Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study | Q48521294 | ||
| A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. | Q51910355 | ||
| Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib | Q57221140 | ||
| Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of diclofenac in the rat | Q73599156 | ||
| Toxicokinetics of indomethacin-induced intestinal permeability in the rat | Q73842574 | ||
| Influence of dosage form on the gastroenteropathy of flurbiprofen in the rat: evidence of shift in the toxicity site | Q74061552 | ||
| The pharmacology of selective inhibition of COX-2 | Q79144905 | ||
| Validation of liquid chromatography and liquid chromatography/tandem mass spectrometry methods for the determination of etoricoxib in pharmaceutical formulations | Q79245300 | ||
| In-line measurement of a drug substance via near infrared spectroscopy to ensure a robust crystallization process | Q80177705 | ||
| The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin | Q80177912 | ||
| Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib | Q83107186 | ||
| P433 | issue | 11 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 703-720 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib | |
| P478 | volume | 47 |
| Q24615651 | A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity |
| Q38262502 | Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs |
| Q64110949 | Effects of the Highly COX-2-Selective Analgesic NSAID Etoricoxib on Human Periodontal Ligament Fibroblasts during Compressive Orthodontic Mechanical Strain |
| Q33934086 | Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocols |
| Q41833844 | Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q91791002 | Intra-articular injection of etoricoxib-loaded PLGA-PEG-PLGA triblock copolymeric nanoparticles attenuates osteoarthritis progression |
| Q48252693 | No effect of the cyclooxygenase-2 inhibitor etoricoxib on pre-emptive and post-operative analgesia in visceral surgery: results of a randomized controlled trial. |
| Q98830220 | Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer |
| Q59103166 | Postoperative Etoricoxib versus Ketoprofen Administration for Pain Management after Total Knee Arthroplasty: A Randomized, Double-Blind Controlled Study |
| Q36356814 | Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model |
| Q39243668 | The first example of a patient with etoricoxib-induced immune hemolytic anemia |
Search more.